disease: patient matched uninvolved colon:6
treatment: Transformed to Mesenchymal Phenotype:3
cell type: Androgen-dependent prostate cancer epithelial cells (LNCaP):11
cell type: Normal prostate epithelial cells (PrEC):12
tissue: metastatic colorectal cancer to the liver:17
transfection: lentivirus carrying control shRNA:3
diagnosis: Sporadic ALS (C9orf72 expansion):3
demographic group: Admixed or American ancestry:3
protein expressed: Flag-Stau1-Mutant (65KDa Isoform):4
cell type: hpSC derived Neural Stem Cells:3
genotype/variation: WT (Luciferase knockdown control):3
differentiation stage: late basophilic erythroblasts:3
cell type: PBMC derived macrophage (HMDM):3
diagnosis: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS):3
treated with: none (untreated control):3
organoid stage: human embryonic stem cells:6
treated with: 100 nM 17ß-estradiol + 25 ng/mL TNFa for 40min:3
tissue type: glioma - non-enhancing FLAIR+ sample:35
treatment: infection with adenovirus with MEK:5
treatment: infection with adenovirus with MEK and EGFR:6
treatment: infection with adenovirus with GFP:6
treated with: None (spontaneously immortal):3
treated with: None (grown until growth arrest):3
transfected with: vectors coding for Myc-KPC1:4
treated with: si RNAs against Integrator 11:5
cell type: senescent cells expressing ZFP36L1mut:3
cell type: senescent cells expressing ZFP36L1wt:3
number of days in vitro in terminal differentiation conditions: 11:19
number of days in vitro in terminal differentiation conditions: 0:5
cell type: Undifferentiated induced pluripotent stem cells:5
developmental stage: 8 week gestation:37
developmental stage: 17 week gestation:40
developmental stage: 10 week gestation:45
developmental stage: 4 week gestation:23
treatment: treated with erlotinib + PBS-1086:3
treatment: infected with empty vector & treated with erlotinib:3
treatment: infected with vector expressing IkB-alpha super-repressor & treated with DMSO:3
treatment: infected with empty vector & treated with DMSO:3
treatment: infected with constitutively-active RelAS536E & treated with erlotinib:3
facs population: LeX+ Glast+ Prominin-low:3
facs population: LeX+ Glast+ Prominin-high:3
group: C: aCD3/aCD28-coated bead expanded nTreg:3
group: B: Allogeneic mature moDC-expanded nTreg:4
history of brucellosis: Chronic brucellosis (<10 years):24
response to treatment of brucellosis: NA; healthy control:47
response to treatment of brucellosis: Leishmaniasis:17
response to treatment of brucellosis: Reinfection:13
cell type: day 6 ES cells differentiating along the cardiac lineage:8
cell type: mesoderm differentiated cells:4
cell type: FACS sorted CD (45+/34+/33+):3
cell origin: prepared from human bone marrow:4
condition: no EGF + A66 (20min preincubation):3
condition: EGF Stimulation + A66 (20min preincubation):15
treatment: 20nM DIS3 siRNA - Dharmacon:3
treatment: 20nM RRP6 siRNA - Dharmacon:3
treatment: 20nM Rrp40 siRNA - Dharmacon:3
treatment: SpliceostatinA - Yoshida Lab:3
bacterial infection: M. abscessus Smooth (MAB-S)-infected:6
tissue: idiopathic nonspecific interstitial pneumonia:3
Indeterminate (neither Pre or Postmenopausal):35
ENDOCERVICAL ADENOCARCINOMA OF THE USUAL TYPE:6
MUCINOUS ADENOCARCINOMA OF ENDOCERVICAL TYPE:17
Peri (6-12 months since last menstrual period):25
Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy):84
HEAD AND NECK SQUAMOUS CELL CARCINOMA BASALOID TYPE:10
LUNG SOLID PATTERN PREDOMINANT ADENOCARCINOMA:5
LUNG BASALOID SQUAMOUS CELL CARCINOMA:17
STOMACH INTESTINAL ADENOCARCINOMA MUCINOUS TYPE:21
STOMACH INTESTINAL ADENOCARCINOMA PAPILLARY TYPE:8
STOMACH  INTESTINAL ADENOCARCINOMA  NOT OTHERWISE SPECIFIED (NOS):82
STOMACH  INTESTINAL ADENOCARCINOMA  TUBULAR TYPE:80
STOMACH ADENOCARCINOMA  SIGNET RING TYPE:12
THYROID PAPILLARY CARCINOMA - FOLLICULAR (>= 99% FOLLICULAR PATTERNED):109
THYROID PAPILLARY CARCINOMA - TALL CELL (>= 50% TALL CELL FEATURES):39
Indeterminate (neither Pre or Postmenopausal):17
Peri (6-12 months since last menstrual period):18
Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement):36
screening chemicals: (trans) Retinoic acid:4
2-[1-HEXYLOXYETHYL]-2-DEVINYL PYROPHEOPHORBIDE-ALPHA (HPPH OR PHOTOCHLOR):4